News und Analysen
GECI INTERNATIONAL : 2020-21 FULL-YEAR EARNINGS
Thanks to the in-depth transformation work carried out, GECI International is reporting a strong improvement in its results and a positive net income figure for the full year
During the Board
DOLFINES (EX DIETSWELL) : Split date on 23 July
PRESS RELEASE Montigny le Bretonneux, July 21, 2021
Division by two of the par value of the share effective on 23 July 2021
In a notice dated 21 July 2021, Euronext set Friday 23 July as the
Sensorion Appoints Ex-Novartis Cell Therapy & Viral Vectors Head Otmane Boussif as Chief Technical Officer
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
DOLFINES (EX DIETSWELL) : Effective date of Share Split
PRESS RELEASE Montigny le Bretonneux, July 19, 2021
Effective date of the division by two of the nominal of the share and the consequent doubling of the number of common shares
The division by two
STREAMWIDE : H1 2021 revenue: EUR 7.9M (up 20%) strong growth driven by the platform business (+35%)
_ STREAMWIDE (FR0010528059 – ALSTW – eligible for the French PEA-PME), the expert in critical
DOLFINES (EX DIETSWELL) : Update on the growth outlook in mid-july 2021
Update on the growth outlook in mid-July 2021
on the occasion of the division by two of the nominal of the share and the consequent doubling of the number of common shares
On the occasion of the
Median Technologies: Financial Communication Schedule for the Second Half Of 2021
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT), announces the publication date for its 2021 half year results (audited) and its Q3, 2021 business performance (unaudited):
Publica
Median Technologies' Business Continues to Grow at a Steady Pace in the First Half of 2021 (Unaudited Figures)
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT) today announces strong business growth for the first half of 2021 (unaudited figures).
For the first half of 2021, Median
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 JUNE 2021 AND PRESENTS AN UPDATE ON THE PROGRESS OF ITS MAIN PROGRAMS
Lyon, 8 July 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between
GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies
GenSight Biologics Reports Topline Results from REFLECT Phase III Clinical Trial, Confirming LUMEVOQ® Efficacy Including Better Efficacy with Bilateral Treatment
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629006120/en/
Figure 1. Best-Corrected Visual Acuity (BCVA) Change
DOLFINES (EX DIETSWELL) : Combined Shareholders' Meeting of DOLFINES
PRESS RELEASE Montigny le Bretonneux, June 29, 2021
Combined Sharehoders' Meeting of DOLFINES
DOLFINES' Combined Shareholders' Meeting was held today in Montigny le
Valbiotis kündigt Durchführung klinischer Studie zur Wirkungsweise von TOTUM-63 durch INAF1 an der Universität Laval in Quebec City in Kooperation mit Nestlé Health Science an
Valbiotis (FR0013254851 - ALVAL, PEA/SME-fähig), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von Stoffwechselkrankheiten
Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action Clinical Study by INAF1 at Laval University in Quebec City, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases
Hub One chooses Streamwide to optimize the use of its private professional 4G/5G network on the Paris-Charles de Gaulle airport platform
Hub One chooses Streamwide to optimize the use of its private professional 4G/5G network on the Paris-Charles de Gaulle airport platform
_ Hub One, an operator of digital technologies for
Hub One elige Streamwide para optimizar el uso de su red profesional privada 4G/5G en la plataforma del aeropuerto París-Charles de Gaulle
Hub One elige Streamwide para optimizar el uso de su red profesional privada 4G/5G en la plataforma del aeropuerto París-Charles de Gaulle
_ Hub One, operador de tecnologías digitales para empresas
PRISMAFLEX INTERNATIONAL : Forecast agenda 2021/2022 for financial press release
PRISMAFLEX INTERNATIONAL : 2020-2021 annual results: Slight decline in results due to the Covid-19 health crisis - Available cash preserved
Significant points 2020-2021
- Downturn in activity limited to -13.8% proforma (-22.5% reported) in an economic climate strongly affected by the health crisis – Return to growth in Q4 (+12.2%
GROUPE LDLC : RECORD 2020/2021 FULL-YEAR RESULTS
LIMONEST, 17 June 2021, 5.45 PM
- 2020/2021 REVENUES UP 46.8% TO €724.1M (UP 25.4% AT CONSTANT CONSOLIDATION SCOPE)
- STRUCTURAL IMPROVEMENT IN GROSS MARGIN TO 22.5% (VS. 19.3% IN 2019/2020)
- RECORD
THERANEXUS : MINUTES OF THE COMBINED GENERAL MEETING OF 16 JUNE 2021
The combined general meeting of shareholders was held on 16 June 2021 at 10:00 am at the Etoile Business Center, 21-25 rue Balzac, 75008 Paris.
The general meeting adopted all the resolutions by a
Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Appoints Marion Ghibaudo as Chief Technical Officer to Lead GS030 Device Engineering
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Valbiotis ernennt Sébastien Bessy, einen internationalen Experten für Consumer Healthcare, zum Chief Operating Marketing and Business Officer
Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Appoints Sébastien Bessy, International Expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer
Press release
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Valbiotis meldet Veröffentlichung der ersten wissenschaftlichen Beiträge zu TOTUM•63 in drei internationalen Fachzeitschriften — Darlegung des an mehreren Stellen ansetzenden Wirkmechanismus
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von